Fibrocell Science, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-07: Form 8-K; Period of report 2014-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-10-03: Form 8-K; Period of report 2014-10-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-09-24: Form 8-K; Period of report 2014-09-24; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2014-09-03: Form 8-K; Period of report 2014-08-28; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-07 | 8-K | 2014-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2014, Fibrocell Science, Inc. issued a press release announcing its financial and operating results for the quarter ended September 30, 2014. | a14-23911_18k.htm |
| 2014-10-03 | 8-K | 2014-10-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As of October 2, 2014, Gregory Weaver is no longer employed by Fibrocell Science, Inc. (the “Company”). | a14-21866_18k.htm |
| 2014-09-24 | 8-K | 2014-09-24 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Fibrocell Science, Inc. (the “Company”) is using the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K in conjunction with its hosting of an R&D Day held on September 24, 2014 in New York, New York. 8.01 On September 24, 2014, the Company issued a press release announcing that it plans to file an investigational new drug application with the U.S. Food and Drug Administration in the first half of fiscal year 2015 for its drug candidate, GM-HDF-COL7 (genetically-modified human dermal fibroblast, collagen VII). | a14-21370_18k.htm |
| 2014-09-03 | 8-K | 2014-08-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 28, 2014, the Compensation Committee of the Board of Directors of Fibrocell Science, Inc. (the “Company”) approved a salary increase for Gregory Weaver, the Company’s Senior Vice President and Chief Financial Officer, from $300,000 to $330,000. | a14-20392_18k.htm |
| 2014-08-18 | 8-K | 2014-08-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On August 18, 2014, Fibrocell Science, Inc. (the “Company”) notified the NYSE MKT of its intention to delist its common stock from the NYSE MKT and to list on The NASDAQ Capital Market of The NASDAQ Stock Market LLC (“NASDAQ”). | a14-19165_18k.htm |
| 2014-08-11 | 8-K | 2014-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2014, Fibrocell Science, Inc. issued a press release announcing its financial and operating results for the quarter ended June 30, 2014. | a14-18719_18k.htm |
| 2014-06-20 | 8-K | 2014-06-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 20, 2014, at the 2014 Annual Meeting of Stockholders (the “Annual Meeting”) of Fibrocell Science, Inc. (the “Company”), the stockholders of the Company approved an amendment to the Company’s 2009 Equity Incentive Plan (the “2009 Plan”) to increase the number of shares of common stock authorized to be issued under the Plan from 2,600,000 to 5,600,000. 5.07 As mentioned above, on June 20, 2014, the Company held its Annual Meeting at the Company’s offices in Exton, Pennsylvania. | a14-15822_18k.htm |
| 2014-06-19 | 8-K | 2014-06-13 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a14-15650_18k.htm |
| 2014-05-19 | 8-K | 2014-05-19 | 2.02 Results of Operations and Financial Condition | 2.02 On May 19, 2014, Fibrocell Science, Inc. (the “Company”) issued a press release announcing its financial and operating results for the quarter ended March 31, 2014. | a14-13000_18k.htm |
| 2014-05-12 | 8-K | 2014-05-06 | 2.02 Results of Operations and Financial Condition; 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 2.02 On May 12, 2014, Fibrocell Science, Inc. (the “Company”) filed a Form 12b-25 (the “Form 12b-25”) with the United States Securities and Exchange Commission to report that it was unable to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014 (the “2014 First Quarter Form 10-Q”) without unreasonable effort and expense. 4.02 (a) Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. | a14-12585_28k.htm |
| 2014-03-17 | 8-K | 2014-03-17 | 2.02 Results of Operations and Financial Condition | 2.02 On March 17, 2014, Fibrocell Science, Inc. issued a press release announcing the financial results for its fourth quarter and full year 2013. | v371771_8k.htm |
| 2014-03-12 | 8-K | 2014-03-12 | 7.01 Regulation FD Disclosure | 7.01 On March 12, 2014, Fibrocell Science, Inc. (the “Company”) posted the presentation attached as exhibit 99.1 on its web site. | v370942_8k.htm |
| 2014-01-23 | 8-K | 2014-01-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 17, 2014, the Compensation Committee of the Board of Directors of Fibrocell Science, Inc. (the “Company”) granted to Gregory Weaver, its Chief Financial Officer and John Maslowski, Vice President of Scientific Affairs, each a ten-year option to purchase 40,000 shares and 20,000 shares, respectively, of the Company’s common stock pursuant to the Company’s 2009 Equity Incentive Plan, as amended. | v366090_8k.htm |
| 2014-01-13 | 8-K | 2014-01-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained in Item 1.01 is hereby incorporated by reference. 7.01 On January 13, 2014, the Company posted the presentation attached as Exhibit 99.2 on its web site. | d659076d8k.htm |